cmf significantly prevented early disease recurrence ( 97 % relapse free on cmf versus 75 % on 5-fu at 12 months ; p less than 0.05 ) and demonstrated survival advantage during the initial 40-month follow-up .
C0950521
cmf
C0016360
fu